Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations | BMC Cancer | Full Text

Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations | BMC Cancer | Full Text

Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations

Osimertinib, a third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), can be used as second-line treatment for lung cancer patients harboring the T790M substitution. Although...

Authors:Yuichiro Takeda, Go Naka, Yoh Yamaguchi, Masao Hashimoto, Manabu Suzuki, Shinyu Izumi and Haruhito Sugiyama

Citation:BMC Cancer 2020 20:951

Content type:Research article

 

Published on: 2 October 2020

• ViewFull Text
 
• ViewPDF